227 related articles for article (PubMed ID: 30544140)
21. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
[TBL] [Abstract][Full Text] [Related]
22. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
23. Predictive biomarkers for anti-TNF alpha therapy in IBD patients.
Kumar M; Murugesan S; Ibrahim N; Elawad M; Al Khodor S
J Transl Med; 2024 Mar; 22(1):284. PubMed ID: 38493113
[TBL] [Abstract][Full Text] [Related]
24. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
[TBL] [Abstract][Full Text] [Related]
25. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis.
Gubatan J; Mitsuhashi S; Longhi MS; Zenlea T; Rosenberg L; Robson S; Moss AC
Cytokine; 2018 Mar; 103():38-45. PubMed ID: 29324259
[TBL] [Abstract][Full Text] [Related]
26. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.
El-Hussuna A; Qvist N; Zangenberg MS; Langkilde A; Siersma V; Hjort S; Gögenur I
BMC Surg; 2018 Nov; 18(1):91. PubMed ID: 30390672
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
28. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
29. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
[TBL] [Abstract][Full Text] [Related]
30. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.
Burke KE; Khalili H; Garber JJ; Haritunians T; McGovern DPB; Xavier RJ; Ananthakrishnan AN
Inflamm Bowel Dis; 2018 Jul; 24(8):1840-1848. PubMed ID: 29718226
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
Dig Liver Dis; 2002 Sep; 34(9):626-30. PubMed ID: 12405248
[TBL] [Abstract][Full Text] [Related]
32. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
33. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis.
Liso M; Verna G; Cavalcanti E; De Santis S; Armentano R; Tafaro A; Lippolis A; Campiglia P; Gasbarrini A; Mastronardi M; Pizarro TT; Cominelli F; Lopetuso LR; Chieppa M
Cell Mol Gastroenterol Hepatol; 2022; 14(1):151-171. PubMed ID: 35314399
[TBL] [Abstract][Full Text] [Related]
36. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
[TBL] [Abstract][Full Text] [Related]
37. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
[TBL] [Abstract][Full Text] [Related]
38. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
39. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
Jessen B; Rodriguez-Sillke Y; Sonnenberg E; Schumann M; Kruglov A; Freise I; Schmidt F; Maul J; Kühl AA; Glauben R; Lissner D; Siegmund B
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):721-731.e1. PubMed ID: 32272247
[TBL] [Abstract][Full Text] [Related]
40. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
